Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Drugs|October 7, 2022
Emerging Targeted Therapies for Early Breast CancerIlana Schlam, Paolo Tarantino, Stefania Morganti, et al.
The American Journal of Surgical Pathology|July 3, 2025
The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular FeaturesS Emily Bachert, Allison M Onken, Allison S Cleary, et al.
Breast Cancer Research and Treatment|January 8, 2022
Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative studyClaire C Conley, McKenzie McIntyre, Nicole A Pensak, et al.
Future Oncology (London, England)|June 22, 2026
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summaryHope S Rugo, Rachel M Layman, Filipa Lynce, et al.
JCO Precision Oncology|September 21, 2018
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer TypesArielle L Heeke, Michael J Pishvaian, Filipa Lynce, et al.
Anticancer Research|March 31, 2018
Racial Disparities in the Molecular Landscape of CancerElisabeth I Heath, Filipa Lynce, Joanne Xiu, et al.
Contemporary Clinical Trials Communications|July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancerFilipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2019
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignanciesFilipa Lynce, Hongkun Wang, Emanuel F Petricoin, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
Breast Cancer Research : BCR|April 1, 2017
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Drugs|October 7, 2022
Emerging Targeted Therapies for Early Breast CancerIlana Schlam, Paolo Tarantino, Stefania Morganti, et al.
The American Journal of Surgical Pathology|July 3, 2025
The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular FeaturesS Emily Bachert, Allison M Onken, Allison S Cleary, et al.
Breast Cancer Research and Treatment|January 8, 2022
Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative studyClaire C Conley, McKenzie McIntyre, Nicole A Pensak, et al.
Future Oncology (London, England)|June 22, 2026
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summaryHope S Rugo, Rachel M Layman, Filipa Lynce, et al.
JCO Precision Oncology|September 21, 2018
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer TypesArielle L Heeke, Michael J Pishvaian, Filipa Lynce, et al.
Anticancer Research|March 31, 2018
Racial Disparities in the Molecular Landscape of CancerElisabeth I Heath, Filipa Lynce, Joanne Xiu, et al.
Contemporary Clinical Trials Communications|July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancerFilipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2019
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignanciesFilipa Lynce, Hongkun Wang, Emanuel F Petricoin, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
Breast Cancer Research : BCR|April 1, 2017
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, et al.
Pageof 10